See more : Caribbean Utilities Company, Ltd. (CUP-U.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Paradigm Biopharmaceuticals Limited (PAR.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paradigm Biopharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Hanjin Transportation Co., Ltd. (002320.KS) Income Statement Analysis – Financial Results
- Global Technology Acquisition Corp. I (GTACW) Income Statement Analysis – Financial Results
- AVG Logistics Limited (AVG.NS) Income Statement Analysis – Financial Results
- Brookfield Asset Management Reinsurance Partners Ltd. (BAMR.TO) Income Statement Analysis – Financial Results
- Global Fashion Group S.A. (GFG.DE) Income Statement Analysis – Financial Results
Paradigm Biopharmaceuticals Limited (PAR.AX)
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.80K | 46.76K | 79.22K | 20.55K | 0.00 | 2.98M | 2.68M | 1.82M | 1.29M | 0.00 | 0.00 |
| Cost of Revenue | 8.99K | 172.48K | 337.00K | 309.20K | 213.12K | 8.35K | 15.35K | 16.63K | 2.54K | 0.00 | 0.00 |
| Gross Profit | 56.81K | -125.72K | -257.78K | -288.65K | -213.12K | 2.98M | 2.67M | 1.81M | 1.29M | 0.00 | 0.00 |
| Gross Profit Ratio | 86.34% | -268.87% | -325.38% | -1,404.61% | 0.00% | 99.72% | 99.43% | 99.09% | 99.80% | 0.00% | 0.00% |
| Research & Development | 58.33M | 52.68M | 39.01M | 33.52M | 12.79M | 7.90M | 6.59M | 4.23M | 2.87M | 157.71K | 0.00 |
| General & Administrative | 6.22M | 6.56M | 7.93M | 8.75M | 4.17M | 2.32M | 2.33M | 1.89M | 1.45M | 219.90K | 231.44K |
| Selling & Marketing | 553.61K | 822.70K | 918.86K | 836.88K | 1.01M | 2.36M | 989.83K | 590.52K | 674.77K | 1.20M | 0.00 |
| SG&A | 6.77M | 6.41M | 7.74M | 8.54M | 3.95M | 4.04M | 2.32M | 1.87M | 1.45M | 1.41M | 231.44K |
| Other Expenses | 0.00 | 6.74M | 8.66M | 8.71M | 3.70M | 1.25M | 2.68M | 1.82M | 1.29M | 0.00 | 0.00 |
| Operating Expenses | 65.10M | 59.09M | 46.75M | 42.06M | 16.75M | 11.94M | 8.91M | 6.11M | 4.32M | 1.57M | 231.44K |
| Cost & Expenses | 65.11M | 59.26M | 47.09M | 42.36M | 16.96M | 11.94M | 8.93M | 6.12M | 4.32M | 1.57M | 231.44K |
| Interest Income | 407.01K | 1.40M | 51.74K | 209.13K | 997.65K | 261.71K | 53.90K | 25.62K | 103.57K | 7.33K | 0.00 |
| Interest Expense | 14.37K | 16.42K | 28.63K | 37.72K | 34.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 146.74K | 153.66K | 193.25K | 210.06K | 213.12K | 8.35K | 15.35K | 16.63K | 2.54K | 1.57M | 231.44K |
| EBITDA | -64.54M | -59.06M | -46.82M | -42.13M | -15.70M | -8.95M | -6.23M | -4.28M | -3.03M | 7.33K | 0.00 |
| EBITDA Ratio | -98,083.89% | -126,309.13% | -59,095.03% | -205,029.78% | 0.00% | -400.01% | -332.20% | -334.98% | -334.42% | 0.00% | 0.00% |
| Operating Income | -65.11M | -59.22M | -47.01M | -42.34M | -16.96M | -11.94M | -8.93M | -6.12M | -4.32M | -1.57M | -231.44K |
| Operating Income Ratio | -98,954.68% | -126,637.75% | -59,338.96% | -206,051.97% | 0.00% | -400.29% | -332.77% | -335.89% | -334.62% | 0.00% | 0.00% |
| Total Other Income/Expenses | 411.88K | 263.60K | -1.48K | -302.21K | 1.01M | -6.88M | 53.90K | 25.62K | 103.57K | 7.33K | 0.00 |
| Income Before Tax | -64.70M | -58.95M | -47.01M | -42.65M | -15.95M | -18.61M | -8.87M | -6.10M | -4.22M | -1.57M | -231.44K |
| Income Before Tax Ratio | -98,328.73% | -126,074.01% | -59,340.83% | -207,522.57% | 0.00% | -623.73% | -330.76% | -334.49% | -326.60% | 0.00% | 0.00% |
| Income Tax Expense | -6.05M | -7.04M | -7.76M | -8.35M | -3.65M | -2.98M | -2.68M | -1.82M | -1.29M | 7.33K | 0.00 |
| Net Income | -58.65M | -51.91M | -39.25M | -34.30M | -12.30M | -15.63M | -6.19M | -4.28M | -2.92M | -1.57M | -231.44K |
| Net Income Ratio | -89,138.58% | -111,013.71% | -49,542.54% | -166,896.27% | 0.00% | -523.73% | -230.76% | -234.49% | -226.60% | 0.00% | 0.00% |
| EPS | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 | -0.05 | -0.04 | -0.03 | -0.05 | 0.00 |
| EPS Diluted | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 | -0.05 | -0.04 | -0.03 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 293.28M | 289.68M | 240.96M | 212.19M | 208.27M | 148.13M | 120.31M | 101.35M | 86.14M | 33.15M | 0.00 |
| Weighted Avg Shares Out (Dil) | 293.28M | 289.68M | 241.82M | 212.19M | 208.27M | 148.13M | 120.31M | 101.35M | 86.14M | 33.15M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports